Sansure Biotech Inc. (688289.SS)
CNY 19.81
(-0.4%)
CNY 19.81
(-0.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1 Billion CNY | -84.46% |
| 2022 | 6.45 Billion CNY | 42.88% |
| 2021 | 4.51 Billion CNY | -5.22% |
| 2020 | 4.76 Billion CNY | 1203.53% |
| 2019 | 365.38 Million CNY | 20.41% |
| 2018 | 303.44 Million CNY | 35.11% |
| 2017 | 224.59 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 388.58 Million CNY | 4.56% |
| 2024 Q2 | 323.54 Million CNY | -16.74% |
| 2024 Q3 | 315.62 Million CNY | -2.45% |
| 2023 Q2 | 232.52 Million CNY | 19.14% |
| 2023 FY | 1 Billion CNY | -84.46% |
| 2023 Q1 | 195.17 Million CNY | -91.81% |
| 2023 Q3 | 204.84 Million CNY | -11.9% |
| 2023 Q4 | 371.65 Million CNY | 81.43% |
| 2022 Q4 | 2.38 Billion CNY | 72.83% |
| 2022 Q2 | 1.25 Billion CNY | -13.17% |
| 2022 Q1 | 1.43 Billion CNY | 15.43% |
| 2022 Q3 | 1.37 Billion CNY | 10.25% |
| 2022 FY | 6.45 Billion CNY | 42.88% |
| 2021 Q1 | 1.16 Billion CNY | 0.44% |
| 2021 Q2 | 865.48 Million CNY | -25.57% |
| 2021 FY | 4.51 Billion CNY | -5.22% |
| 2021 Q4 | 1.24 Billion CNY | 0.68% |
| 2021 Q3 | 1.23 Billion CNY | 43.14% |
| 2020 FY | 4.76 Billion CNY | 1203.53% |
| 2020 Q4 | 1.15 Billion CNY | -23.09% |
| 2020 Q1 | 399.58 Million CNY | 227.44% |
| 2020 Q2 | 1.7 Billion CNY | 325.55% |
| 2020 Q3 | 1.5 Billion CNY | -11.48% |
| 2019 FY | 365.38 Million CNY | 20.41% |
| 2019 Q3 | 76.6 Million CNY | -9.78% |
| 2019 Q2 | 84.91 Million CNY | 3.77% |
| 2019 Q1 | 81.83 Million CNY | 0.0% |
| 2019 Q4 | 122.03 Million CNY | 59.29% |
| 2018 FY | 303.44 Million CNY | 35.11% |
| 2017 FY | 224.59 Million CNY | 0.0% |